Department of Medical Oncology, Centre Leon Berard and University Claude Bernard Lyon I, Lyon, France.
Future Oncol. 2018 May;14(10s):3-13. doi: 10.2217/fon-2018-0074.
Surgery (+ radiation therapy in selected cases) is standard treatment for adult-type localized soft tissue sarcoma (STS). Accumulating randomized clinical evidence also supports adjuvant chemotherapy as a treatment option, although this remains contentious. Doxorubicin (± ifosfamide) is the standard first-line systemic treatment for advanced STS; however, newer chemotherapeutic agents may improve outcomes achieved with single-agent doxorubicin. In a Phase II study, adding olaratumab to doxorubicin markedly improved overall survival. Agents for second- and further lines include trabectedin, which combines long-term tumor stabilization with good quality of life, and gemcitabine + docetaxel which can produce a marked clinical response although at the cost of high toxicity. Pazopanib, eribulin, aldoxorubicin and regorafenib are other options for use in advanced STS.
手术（在某些情况下联合放射治疗）是成人局限性软组织肉瘤（STS）的标准治疗方法。越来越多的随机临床试验证据也支持辅助化疗作为一种治疗选择，尽管这仍然存在争议。多柔比星（±异环磷酰胺）是治疗晚期 STS 的标准一线全身治疗药物；然而，新型化疗药物可能会提高单药多柔比星的疗效。在一项 II 期研究中，将奥拉单抗与多柔比星联合使用显著改善了总生存期。二线和三线治疗药物包括曲贝替定，它能在长期稳定肿瘤的同时保持良好的生活质量，以及吉西他滨+多西他赛，虽然毒性较高，但能产生显著的临床反应。帕唑帕尼、艾立布林、醛基多柔比星和瑞戈非尼也是晚期 STS 的其他治疗选择。
